APA

Harb J. G., Neviani P., Chyla B. J., Ellis J. J., Ferenchak G. J., Oaks J. J., Walker C. J., Hokland P., Roy D. C., Caligiuri M. A., Marcucci G., Huettner C. S. & Perrotti D. (20131210). Bcl-xL anti-apoptotic network is dispensable for development and maintenance of CML but is required for disease progression where it represents a new therapeutic target. : Leukemia.

Chicago

Harb J G, Neviani P, Chyla B J, Ellis J J, Ferenchak G J, Oaks J J, Walker C J, Hokland P, Roy D C, Caligiuri M A, Marcucci G, Huettner C S and Perrotti D. 20131210. Bcl-xL anti-apoptotic network is dispensable for development and maintenance of CML but is required for disease progression where it represents a new therapeutic target. : Leukemia.

Harvard

Harb J. G., Neviani P., Chyla B. J., Ellis J. J., Ferenchak G. J., Oaks J. J., Walker C. J., Hokland P., Roy D. C., Caligiuri M. A., Marcucci G., Huettner C. S. and Perrotti D. (20131210). Bcl-xL anti-apoptotic network is dispensable for development and maintenance of CML but is required for disease progression where it represents a new therapeutic target. : Leukemia.

MLA

Harb J G, Neviani P, Chyla B J, Ellis J J, Ferenchak G J, Oaks J J, Walker C J, Hokland P, Roy D C, Caligiuri M A, Marcucci G, Huettner C S and Perrotti D. Bcl-xL anti-apoptotic network is dispensable for development and maintenance of CML but is required for disease progression where it represents a new therapeutic target. : Leukemia. 20131210.